NedNotes (not blog): COVIData sweep 30oct20
B.L.U.F. (bottom-line, up front) : Not much new to report; at a possible inflection point. Biggest challenge appears to be cultural aversion to tracing surveys and pandemic fatigue; warnings coming in from Europe. NOTE: the basis for data now aggregates four sources – Johns Hopkins , Microsoft , The New York Times , Worldometers . Introduction News is mixed this week as America’s second wave may mimic Europe’s spike . Data collected conflict on post-infection immunity (i.e., five months versus three ), declining mortality versus new mutations , and some possible treatments being deferred (e.g., Eli Lilly ), perhaps due to cyber-attacks . One bright spot on cures: Regeneron’s testing of its anti-body hybrid drug indicates preliminary effectiveness among eight hundred test subjects. One must remember two over-riding facts of life-&-death in 2020: that this epidemic is expected to have a high penetration and low mortality rates; as well as, that miracle cures , lik...